Is Clinuvel Pharmaceuticals Ltd. a good dividend stock?

Clinuvel Pharmaceuticals Ltd. (CUVL) is a dividend-paying stock with a current dividend yield of 0.40%. Review its dividend history, payout consistency and growth to judge whether it fits your income strategy.

What is CUVL's dividend yield?

The dividend yield for CUVL stock is currently 0.40%.

How much does CUVL pay in dividends per year?

Clinuvel Pharmaceuticals Ltd. pays an annual dividend of $0.0264 per share over the trailing twelve months.

How often does CUVL pay dividends?

CUVL stock pays dividends annually.

Is CUVL's dividend growing?

Clinuvel Pharmaceuticals Ltd.'s 3-year dividend CAGR is 2%.

CUVL Stock Price, Chart, Stats & News

Clinuvel Pharmaceuticals Ltd.

Save

Overview Dividend safety Dividends Fundamentals

Clinuvel Pharmaceuticals Ltd. (CUVL) is a dividend-paying stock with a current dividend yield of 0.40% as of Sep 4, 2026. It pays $0.0264 per share over the trailing twelve months and distributes annually. Its dividend has grown at a 9.75% 5-year compound annual rate.

328.79M

Market cap

–

Current P/E

–

Forward P/E

0.40%

Dividend yield

$0.0264

CUVL dividend

Dividend safety

Moderate

Dividend coverage is moderate for CUVL — worth a closer look at the full safety breakdown.

See the safety analysis

CUVL chart

Loading chart...

About

Health care

Sector

Medical - Pharmaceuticals

Industry

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.